ArticleBiomolecules & therapeutics2019
Sleep Promoting Effect of Luteolin in Mice via Adenosine A1 and A2A Receptors.
Article in Biomolecules & therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 47 citations in OpenAlex.
- Combined Administration of Cannabidiol and L-Theanine Improves Sleep-Related Outcomes in Caffeine-Induced Sleep Disturbances Mouse Model.Biomolecules & therapeutics · 2026Article
- The Hypnotic Effect of Spinosin Is Mediated by Adenosine ANutrients · 2026Article
- Adenosine ABiomolecules & therapeutics · 2026Review
- Chrysanthemum morifolium extract protects HT22 cells from oxidative stress and enhances sleep via GABAergic modulation: contribution of luteolin-7-glucoside.Journal of the science of food and agriculture · 2026Article
- Role of Adenosine Receptors in Sleep Deprivation-Induced Depression-Like Behaviors.Biomolecules & therapeutics · 2026Article
- Prediction of the therapeutic mechanism of Sugemule-4 in insomnia treatment using network pharmacology and molecular docking.Medicine · 2025Article
- Mechanisms of Suanzaoren () and its processed products in treating insomnia: an integrated study based on network pharmacology and metabolomics.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Article
- Neuroactive Phytochemicals as Multi-Target Modulators of Mental Health and Cognitive Function: An Integrative Review.International journal of molecular sciences · 2025Review
- Sleep Deprivation and Alzheimer's Disease: A Review of the Bidirectional Interactions and Therapeutic Potential of Omega-3.Brain sciences · 2025Review
- Oral supplement in healthy older adults to support physical fitness and mental wellbeing.Frontiers in nutrition · 2025Article
- Article
- Heukharang (Sleep and biological rhythms · 2024Article
- Dietary Intake of Flavonoids Associated with Sleep Problems: An Analysis of Data from the National Health and Nutrition Examination Survey, 2007-2010.Brain sciences · 2023Article
- Chaihu-Longgu-Muli decoction improves sleep disorders by restoring orexin-A function in CKD mice.Frontiers in endocrinology · 2023Article
- Effect of the Citrus Flavone Nobiletin on Circadian Rhythms and Metabolic Syndrome.Molecules (Basel, Switzerland) · 2022Review
- Article
- Investigation on the Anticonvulsant Potential of Luteolin and Micronized Luteolin in Adult Zebrafish (Danio rerio).Neurochemical research · 2021Article
- Study on the Sleep-Improvement Effects ofFoods (Basel, Switzerland) · 2021Article
- Integrated Screening of Effective Anti-Insomnia Fractions of Zhi-Zi-Hou-Po Decoction viaACS omega · 2021Article
- Paving Luteolin Therapeutic Potentialities and Agro-Food-Pharma Applications: Emphasis onOxidative medicine and cellular longevity · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Luteolin, a widespread flavonoid, has been known to have neuroprotective activity against various neurologic diseases such as epilepsy, and Alzheimer's disease. However, little information is available regarding the hypnotic effect of luteolin. In this study, we evaluated the hypnotic effect of luteolin and its underlying mechanism. In pentobarbital-induced sleeping mice model, luteolin (1, and 3 mg/kg, p.o.) decreased sleep latency and increased the total sleep time. Through electroencephalogram (EEG) and electromyogram (EMG) recording, we demonstrated that luteolin increased non-rapid eye movement (NREM) sleep time and decreased wake time. To evaluate the underlying mechanism, we examined the effects of various pharmacological antagonists on the hypnotic effect of luteolin. The hypnotic effect of 3 mg/kg of luteolin was not affected by flumazenil, a GABAA receptorbenzodiazepine (GABAAR-BDZ) binding site antagonist, and bicuculine, a GABAAR-GABA binding site antagonist. On the other hand, the hypnotic effect of 3 mg/kg of luteolin was almost completely blocked by caffeine, an antagonist for both adenosine A1 and A2A receptor (A1R and A2AR), 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX), an A1R antagonist, and SCH-58261, an A2AR antagonist. From the binding affinity assay, we have found that luteolin significantly binds to not only A1R but also A2AR with IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.